Develops and manufactures in vitro diagnostics (IVD) products. Offers rapid antigen tests for SARS-CoV-2 and influenza A/B. Now — the numbers.
This is an established company with proven profits.
Average growth of 18% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $11.9M would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 88% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 74% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 18% a year on average.
There is $11.9M in the vault; even if every debt were paid off, $11.9M would remain.
The company’s market value is 43 times its annual profit. Even a small disappointment could hit the price hard.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 10/100. For a turnaround signal, the stock first needs to close the gap with the market.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 40/100.
On our five-subject report card, NNNN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NNNN is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.